Purpose: We evaluated the efficacy of testosterone gel (T-gel) alone and in combination with sildenafil in hypogonadal patients with erectile dysfunction (ED).
Androgens have a profound role in male sexual function and in erectile physiology. 1 Monga et al reported that hypogonadal patients with erectile dysfunction (ED) may benefit from testosterone supplement by achieving improved quality of erections and libido, 2 and Mulhall et al questioned the role of testosterone supplement (TS) in restoring erectile function (EF) in this population. 3 We designed this prospective open label study to evaluate the efficacy of testosterone gel (T-gel) alone and in combination with sildenafil in alleviating sexual dysfunction among hypogonadal patients in whom TS therapy alone failed.
MATERIAL AND METHODS

Subjects.
A total of 52 hypogonadal men (total testosterone blood level less than 400 ng/dl on 2 blood samples) with ED were recruited. 4 Participants signed a consent form which had been approved by the institutional review board. Medical and sexual history was obtained, and the men underwent physical examination, psychological profile and endocrine evaluation for the etiology of hypogonadism. Men with Peyronie's disease, penile curvature and history of penile surgery (except circumcision) were excluded from the study, as were those who had used sildenafil or any form of testosterone supplement in the past (3 patients). Thus, 49 men with idiopathic hypogonadism and a steady female partner were recruited. Diagnosis of ED was established according to the National Institutes of Health statement on the condition. 5 Sexual function was assessed using the International Index of Erectile Function (IIEF) questionnaire, validated and translated into Hebrew, and a global assessment question (GAQ). The IIEF assessment of sexual function is based on the scores of 5 domains (see figure) . The final score for each domain was computed as the sum of the scores assigned to the individual questions in each domain. The global assessment question, "Overall, are you satisfied with your erectile function?" was answered with a "yes" or "no." Patients not satisfied with EF (an answer of no to the GAQ) and whose EF score on the IIEF questionnaire was less than 26 were enrolled in the study. 6 Study medications. Patients on testosterone supplement were treated with topical AndroGel (Besins International, Paris, France). The formulation consists of hydroalcoholic gel containing 5 gm of 1% (10 mg/gm) testosterone. They applied testosterone gel (T-gel) daily from 1 container to upper arm and shoulders, and washed their hands with soap and water immediately afterwards. Patients who received sildenafil ingested a 100 mg tablet 1 hour before intercourse. Concomitant consumption of alcohol and fatty foods was forbidden.
Study protocol. Before treatment initiation, and at 3 and 6 months during the study, blood tests for total testosterone (TT), bioavailable testosterone (BT) and prostate specific antigen (PSA) were drawn, and sexual function was assessed (IIEF and GAQ). Lower urinary tract symptoms were assessed using the International Prostate Symptom Score (I-PSS) questionnaire. After 3 months of treatment with TS Submitted for publication May 3, 2004 . Nothing to disclose. * Correspondence: Department of Urology, Tel Aviv Sourasky Medical Center, 6 Weizman St., Tel Aviv 64239, Israel (telephone: ϩ972-3-6973587; FAX: ϩ972-3-6973798; e-mail: surge04@post.tau.ac.il).
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alone, patients not satisfied with EF (a "no" answer to the GAQ) were treated with a combination of sildenafil and TS for another 3 months. These patients comprised the combination therapy group. All study parameters were reevaluated after another 3 months. Data were analyzed using 1-and 2-way analysis of variation with repeated measures.
RESULTS
A total of 49 men (age range 35 to 74 years) comprised the study cohort. Each had at least 1 comorbidity such as hypertension, diabetes mellitus, or cardiovascular disease, not taking nitrates, that could potentially contribute to the ED. Mean ED duration was 20.2 months (range 2 to 48 months). None of our patients had a body mass index greater than 30 kg/m 2 . All patients achieved normal TT and BT levels, and an improvement in sexual desire (SD) domain score (from 4 Ϯ 0.8 to 8.4 Ϯ 1.8, p Ͻ0.001) 3 months after TS initiation (table  1) . Following treatment with T-gel 31 of the 49 participants (63.3%) reported significant improvement in the SD domain (from a mean of 4.0 Ϯ 0.8 to 8.9 Ϯ 0.5, p Ͻ0.001) and in the EF domain (from a mean of 15.0 Ϯ 1.9 to 26 Ϯ 2.2, p Ͻ0.001, part A of figure). All patients in this group were satisfied with TS alone and answered "yes" to the GAQ, thus comprising the TS alone group.
A total of 17 patients answered "no" to the GAQ in spite of normalization of TT and BT values, significant improvement of SD domain scores and improvement of the EF domain from a mean of 13.6 Ϯ 1.9 to 22 Ϯ 1.9 following T-gel alone. The EF domain score of each of these patients remained less than 26. Those 17 patients were treated with a combination of T-gel and sildenafil for another 3 months, and comprised the combination therapy group. After 3 months of combination therapy there was an additional significant (p Ͻ0.001) improvement in mean EF score (to 27 Ϯ 0.8), all reported an EF score of 26 or greater and all now answered positively to the GAQ. No further statistically significant improvement was noted in the other IIEF domains in the combination group compared to that seen after the first 3 months of T-gel application (part B of figure) .
There was no statistically significant difference between the treated groups in terms of age, comorbidity, TT, BT, PSA or I-PSS values before and after T-gel treatment (table 2) . No change in PSA and I-PSS values before and after treatment was recorded, nor was any correlation demonstrated between comorbidity and response to treatment.
There were 9 patients who reported irritation at the T-gel application site but it was not bothersome enough to require discontinuation. One patient dropped out of the study due to worsening of lower urinary tract symptoms. This patient had completed 3 months of treatment with T-gel alone and was satisfied with the improvement that had been achieved in EF. His data were analyzed in the T-gel group. Urinary retention developed in another patient in the combination therapy group after 5 months of treatment and it was resolved after a few days of catheterization.
DISCUSSION
The effects of testosterone during embryonic differentiation and pubertal development are well delineated, 7, 8 but the causal relationship between altered androgen levels and ED has not yet been established. Greenstein et al reported that men may still have functional erections with castration blood levels of testosterone 9 and the National Institutes of Health Consensus Development Panel on Impotence concluded that some hypogonadal men with ED may benefit from testosterone supplement. 5 Evaluation of blood level of testosterone is a fundamental step in the search for a correctable/reversible cause of ED. Abnormal testosterone levels in men with ED were reported to be 5.7% to 18.7% by Bodie et al 10 and Earle and Stuckey. 11 Thus, management of hypogonadism with TS may restore sexual function and achieve significant benefits in terms of libido, general well-being, osteoporosis, muscle IIEF scores of study groups before and after treatment. A, IIEF scores of T-gel alone group (31 patients). B, IIEF scores of T-gel and sildenafil group (17 patients strength, mental acuity and growth hormone levels, all of which may be negatively affected by low testosterone levels. 1 Traditional TS therapy has been found ineffective in restoring EF in a considerable number of hypogonadal men. Morales et al reported that the oral testosterone undecanoate restored plasma testosterone levels in all patients, and that 61% had an improvement in sexual attitudes and performance. 12 The testosterone esters enanthate and cypionate require injection of the medication every 10 to 21 days. This TS is rapid and effective therapy but it bears a significant disadvantage due to a roller-coaster effect, leading to fluctuation in mood, libido and energy levels, and perhaps causing breast tenderness and gynecomastia. 12 Transdermal testosterone therapy is the most effective route for restoring the circadian pattern of testosterone production of the testes. 1 T-gel supplement was found to be effective in restoring testosterone blood levels, improving sexual function and mood, increasing lean mass and muscle strength, and decreasing fat mass in hypogonadal men with less skin irritation and fewer cases of discontinuation compared to the recommended dose of a testosterone patch. 13 In our study after 3 months of T-gel application normalization of testosterone blood level was achieved in all patients with 63.3% reporting significant improvement in the SD and EF domains. Our results are similar to those with oral, transdermal patch and intramuscular TS. 12, 13 Hypogonadism is rarely the main or the single explanation for ED. 14 Thus, it is reasonable that not all hypogonadal men in the current study had improved EF after normalization of blood testosterone alone. This group of patients did benefit from the combination treatment of sildenafil and T-gel, thus the hypogonadal effect on ED was, indeed, the main one among men who were satisfied with T-gel alone, insofar as sexual function improved without further intervention. Comorbidity components probably had a greater etiological role in the combination treatment group. Morelli et al demonstrated that androgens positively regulate phosphodiesterase type 5 in rabbit corpora cavernosa strips. 15 Their data may explain the effect of combined sildenafil and T-gel in improving IIEF scores in all patients in the combination therapy group. Aversa et al reported that short-term transdermal testosterone supplement (5 mg daily) in patients with ED showing testosterone levels in the low to normal range and not responding to sildenafil alone because of arterial insufficiency (evaluated by dynamic color duplex ultrasound) led to higher arterial inflow to the penis and better cavernous vasodilatation improvement in the erectile response to sildenafil. 16 At first glance it would seem easier to give sildenafil to hypogonadal men as first line therapy for ED, but sildenafil alone appears to be less effective in men with hypogonadism. Kalinchenko et al evaluated the effect of oral testosterone undecanoate on ED associated with diabetes mellitus in patients in whom sildenafil therapy alone failed. 17 Oral testosterone treatment alone restored testosterone blood levels to normal and increased libido, while combined sildenafil therapy with oral testosterone supplement induced satisfactory erections as assessed by the IIEF scale in 84 of 120 (70%) sildenafil nonresponders. 17 Shabsigh et al compared the efficacy of T-gel versus placebo as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who did not respond to sildenafil alone, and concluded that T-gel taken with sildenafil may be beneficial in improving erectile function. 4 It seems that for a favorable improvement of EF in hypogonadal men there may be a need for combined therapy with testosterone supplement and sildenafil.
Two patients discontinued treatment due to urination difficulties. A possible explanation for one case is the effect of TS on prostate size affecting bladder outlet obstruction. As in all patients in their 50s and older, monitoring for prostate cancer using PSA measurements and digital rectal examination is recommended for hypogonadal men who are undergoing TS therapy.
CONCLUSIONS
Our results suggest that T-gel is an effective and safe treatment for hypogonadal patients with impaired sexual function. The combination of sildenafil and T-gel has a beneficial effect on hypogonadal patients with erectile dysfunction whose condition did not improve satisfactorily with T-gel treatment alone.
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